NYSEMKT:CATX
Perspective Therapeutics, Inc. Stock News
$1.07
-0.0900 (-7.76%)
At Close: Jun 14, 2024
Perspective Therapeutics Announces Inclusion in the Russell 3000® Index
07:00am, Wednesday, 12'th Jun 2024
SEATTLE, June 12, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced tre
Perspective Therapeutics Announces 1-for-10 Reverse Stock Split
07:00am, Tuesday, 11'th Jun 2024
SEATTLE, June 11, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced trea
Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting
04:10pm, Monday, 10'th Jun 2024
SEATTLE, June 10, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced tr
Perspective Therapeutics Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
08:01am, Friday, 24'th May 2024
SEATTLE, May 24, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treat
Insider Trading is Good News for These Stocks
09:45am, Monday, 20'th May 2024
Insiders are buying these hot stocks that have ample upside for investors. The list includes pharma, entertainment, and financial stocks and Berkshire buys.
Perspective Therapeutics to Present at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2024
07:00am, Monday, 20'th May 2024
SEATTLE, May 20, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced trea
CATX Stock Earnings: Perspective Therapeutics Meets EPS for Q1 2024
11:54am, Wednesday, 15'th May 2024
Perspective Therapeutics (NYSEMKT: CATX ) just reported results for the first quarter of 2024. Perspective Therapeutics reported earnings per share of -2 cents.
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 Results
07:00am, Wednesday, 15'th May 2024
SEATTLE, May 15, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treat
Perspective Therapeutics to Participate at Upcoming May Investor Conferences
07:00am, Friday, 03'rd May 2024
SEATTLE, May 03, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced tr
Perspective Therapeutics to Provide Recent Business Highlights and Report First Quarter 2024 Financial Results
07:00am, Thursday, 02'nd May 2024
SEATTLE, May 02, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout
SEATTLE, April 30, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throug
Perspective Therapeutics to Participate at Upcoming April Investor Conferences
08:00am, Monday, 08'th Apr 2024
SEATTLE, April 08, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results
07:30am, Thursday, 28'th Mar 2024
SEATTLE, March 28, 2024 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers througho
Perspective Therapeutics Announces $87.4 Million Private Placement
09:45am, Monday, 04'th Mar 2024
SEATTLE, March 04, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced tr
Earnings Preview: Perspective Therapeutics (CATX) Q4 Earnings Expected to Decline
11:05am, Thursday, 08'th Feb 2024
Perspective Therapeutics (CATX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.